Copyright © 1997 by the European Society of Cardiology.
© 1997 The European Society of Cardiology
Prognostic value of plasma endothelin-1 in patients with chronic heart failure




*Departments of Cardiology, Pitié-Salpêiriére Hospital, Institut Fédératif de Recherche Physiopathologique et Génétique Cardiovasculaire Paris, France
Departments of Pharmacology, Pitié-Salpêiriére Hospital, Institut Fédératif de Recherche Physiopathologique et Génétique Cardiovasculaire Paris, France
Departments of Biochemistry, Pitié-Salpêiriére Hospital, Institut Fédératif de Recherche Physiopathologique et Génétique Cardiovasculaire Paris, France
Departments of Biostatistics, Pitié-Salpêiriére Hospital, Institut Fédératif de Recherche Physiopathologique et Génétique Cardiovasculaire Paris, France
revised 10 September 1996; accepted 13 September 1996.
Correspondence: Prof. M. Komajda, Service de Cardiologie, Hôpital Pitié-Salp$trière, 47-83 Boulevard de l'Hôpital. 75013 Paris, France
Abstract
AIMS: Endothelin-1 is a potent vasoconstrictive and multifunctional peptide. Elevated concentrations have been reported in congestive heart failure. We hypothesized that the level of endothelin-1 in plasma is a prognostic marker in congestive heart failure.
METHODS AND RESULTS: Plasma levels of endothelin-1 were measured by radioimmunoassay in 120 congestive heart failure patients with ischaemic or non-ischaemic cardiomyopathy (mean ejection fraction 28±11%, in New York Heart Association (NYHA) functional class I: 21, class II: 35, class III: 61, class IV: 3). During a median follow-up of 361±338 days, 14 cardiac deaths occurred. In the univariate Cox model, endothelin-1 was the most powerful prognostic marker among the variables tested (P=0 0001). A multivariate model, including plasma atrial natriuretic peptide and noradrenaline, NYHA class, age, and echocardiographic left ventricular end-diastolic diameter index was highly predictive of mortality (P=0·00008), but only endothelin-1 remained significantly associated with outcome (P=0·02). Patients with plasma endothelin-1
5 pg . ml1 had a higher mortality rate than those with endothelin-1<5 pg. ml1 (21% vs 4%, P=0·001).
CONCLUSION: Our results suggest that elevated endothelin-1 plasma levels are associated with a poor prognosis and routine plasma endothelin-1 determination provides important prognostic information in mild to moderate heart failure.
Key Words: Endothelin-1 chronic heart failure prognosis
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
C.-K. Sun, F.-Y. Lee, J.-J. Sheu, C.-M. Yuen, S. Chua, S.-Y. Chung, H.-T. Chai, Y.-T. Chen, Y.-H. Kao, L.-T. Chang, et al. Early Combined Treatment with Cilostazol and Bone Marrow-Derived Endothelial Progenitor Cells Markedly Attenuates Pulmonary Arterial Hypertension in Rats J. Pharmacol. Exp. Ther., September 1, 2009; 330(3): 718 - 726. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Bredin, A. Olsson, and A. Franco-Cereceda No Additive Effect of Passive Containment Surgery in Patients With Aortic Regurgitation and Left Ventricular Dilation Ann. Thorac. Surg., August 1, 2007; 84(2): 510 - 513. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Vazir, P.C. Hastings, M. Dayer, H.F. McIntyre, M.Y. Henein, P.A. Poole-Wilson, M.R. Cowie, M.J. Morrell, and A.K. Simonds A high prevalence of sleep disordered breathing in men with mild symptomatic chronic heart failure due to left ventricular systolic dysfunction Eur J Heart Fail, March 1, 2007; 9(3): 243 - 250. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Roig Usefulness of neurohormonal markers in the diagnosis and prognosis of heart failure Eur. Heart J. Suppl., September 1, 2006; 8(suppl_E): E12 - E17. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Sauvageau, E. Thorin, A. Caron, and J. Dupuis Evaluation of endothelin-1-induced pulmonary vasoconstriction following myocardial infarction. Experimental Biology and Medicine, June 1, 2006; 231(6): 840 - 846. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Bredin and A. Franco-Cereceda Reversed remodelling in dilated cardiomyopathy by passive containment surgery is associated with decreased circulating levels of endothelin-1 Eur. J. Cardiothorac. Surg., March 1, 2006; 29(3): 299 - 303. [Abstract] [Full Text] [PDF] |
||||
![]() |
S J Leslie, J C S Spratt, S P McKee, F E Strachan, D E Newby, D B Northridge, M A Denvir, and D J Webb Direct comparison of selective endothelin A and non-selective endothelin A/B receptor blockade in chronic heart failure Heart, July 1, 2005; 91(7): 914 - 919. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. S. Gardner, V. Chong, I. Morton, and T. A. McDonagh N-terminal brain natriuretic peptide is a more powerful predictor of mortality than endothelin-1, adrenomedullin and tumour necrosis factor-{alpha} in patients referred for consideration of cardiac transplantation Eur J Heart Fail, March 2, 2005; 7(2): 253 - 260. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. J. Cowburn, J. G.F. Cleland, T. A. McDonagh, J. D. McArthur, H. J. Dargie, and J. J. Morton Comparison of selective ETA and ETB receptor antagonists in patients with chronic heart failure Eur J Heart Fail, January 1, 2005; 7(1): 37 - 42. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. de Groote, J. Dagorn, B. Soudan, N. Lamblin, E. McFadden, and C. Bauters B-type natriuretic peptide and peak exercise oxygen consumption provide independent information for risk stratification in patients with stable congestive heart failure J. Am. Coll. Cardiol., May 5, 2004; 43(9): 1584 - 1589. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Zolk, F. Munzel, and T. Eschenhagen Effects of chronic endothelin-1 stimulation on cardiac myocyte contractile function Am J Physiol Heart Circ Physiol, April 1, 2004; 286(4): H1248 - H1257. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Motte, R. van Beneden, J. Mottet, B. Rondelet, M. Mathieu, X. Havaux, P. Lause, C. Clercx, J.-M. Ketelslegers, R. Naeije, et al. Early activation of cardiac and renal endothelin systems in experimental heart failure Am J Physiol Heart Circ Physiol, December 1, 2003; 285(6): H2482 - H2491. [Abstract] [Full Text] [PDF] |
||||
![]() |
R.S. Gardner, F. Ozalp, A.J. Murday, S.D. Robb, and T.A. McDonagh N-terminal pro-brain natriuretic peptide: A new gold standard in predicting mortality in patients with advanced heart failure Eur. Heart J., October 1, 2003; 24(19): 1735 - 1743. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Lindenfeld, J. K. Ghali, H. J. Krause-Steinrauf, S. Khan, K. Adams Jr, S. Goldman, M. A. Peberdy, C. Yancy, S. Thaneemit-Chen, R. L. Larsen, et al. Hormone replacement therapy is associated with improved survival in women with advanced heart failure J. Am. Coll. Cardiol., October 1, 2003; 42(7): 1238 - 1245. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. O'Connor, W. A. Gattis, K. F. Adams Jr, V. Hasselblad, B. Chandler, A. Frey, I. Kobrin, M. Rainisio, M. R. Shah, J. Teerlink, et al. Tezosentan in patients with acuteheart failure and acute coronary syndromes: Results of the randomized intravenous tezosentan study (ritz-4) J. Am. Coll. Cardiol., May 7, 2003; 41(9): 1452 - 1457. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. S. Gottlieb The neurohormonal paradigm:have we gone too far? J. Am. Coll. Cardiol., May 7, 2003; 41(9): 1458 - 1459. [Full Text] [PDF] |
||||
![]() |
A. P Bolger, A. J.S Coats, and M. A Gatzoulis Congenital heart disease: the original heart failure syndrome Eur. Heart J., May 2, 2003; 24(10): 970 - 976. [Abstract] [Full Text] [PDF] |
||||
![]() |
A.-Y. Chong, A.D. Blann, and G.Y.H. Lip Assessment of endothelial damage and dysfunction: observations in relation to heart failure QJM, April 1, 2003; 96(4): 253 - 267. [Full Text] [PDF] |
||||
![]() |
A. P. Bolger, R. Sharma, W. Li, M. Leenarts, P. R. Kalra, M. Kemp, A. J.S. Coats, S. D. Anker, and M. A. Gatzoulis Neurohormonal Activation and the Chronic Heart Failure Syndrome in Adults With Congenital Heart Disease Circulation, July 2, 2002; 106(1): 92 - 99. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Ceconi, R. Ferrari, T. Bachetti, C. Opasich, M. Volterrani, B. Colombo, G. Parrinello, and A. Corti Chromogranin A in heart failure. A novel neurohumoral factor and a predictor for mortality Eur. Heart J., June 2, 2002; 23(12): 967 - 974. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Hurlimann, F. Ruschitzka, and T.F. Luscher The relationship between the endothelium and the vessel wall Eur. Heart J. Suppl., February 1, 2002; 4(suppl_A): A1 - A7. [Abstract] [PDF] |
||||
![]() |
P.J. Cowburn and J.G.F. Cleland Endothelin antagonists for chronic heart failure: do they have a role? Eur. Heart J., October 1, 2001; 22(19): 1772 - 1784. [PDF] |
||||
![]() |
P. R Kalra, S. D Anker, and A. J.S Coats Water and sodium regulation in chronic heart failure: the role of natriuretic peptides and vasopressin Cardiovasc Res, August 15, 2001; 51(3): 495 - 509. [Full Text] [PDF] |
||||
![]() |
T A McDonagh, A D Cunningham, C E Morrison, J J V McMurray, I Ford, J J Morton, and H J Dargie Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population Heart, July 1, 2001; 86(1): 21 - 26. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. E. Spieker, G. Noll, F. T. Ruschitzka, and T. F. Luscher Endothelin receptor antagonists in congestive heart failure: a new therapeutic principle for the future? J. Am. Coll. Cardiol., May 1, 2001; 37(6): 1493 - 1505. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Gomberg-Maitland, D. A. Baran, and V. Fuster Treatment of Congestive Heart Failure: Guidelines for the Primary Care Physician and the Heart Failure Specialist Arch Intern Med, February 12, 2001; 161(3): 342 - 352. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. L. Clark Perioperative Treatment of Congestive Heart Failure Seminars in Cardiothoracic and Vascular Anesthesia, November 1, 2000; 4(4): 223 - 235. [Abstract] [PDF] |
||||
![]() |
M. M. Givertz, W. S. Colucci, T. H. LeJemtel, S. S. Gottlieb, J. M. Hare, M. T. Slawsky, C. V. Leier, E. Loh, J. M. Nicklas, and B. E. Lewis Acute Endothelin A Receptor Blockade Causes Selective Pulmonary Vasodilation in Patients With Chronic Heart Failure Circulation, June 27, 2000; 101(25): 2922 - 2927. [Abstract] [Full Text] [PDF] |
||||
![]() |
F Pousset, F Masson, O Chavirovskaia, R Isnard, A Carayon, J.L Golmard, P Lechat, D Thomas, and M Komajda Plasma adrenomedullin, a new independent predictor of prognosis in patients with chronic heart failure Eur. Heart J., June 2, 2000; 21(12): 1009 - 1014. [Abstract] [PDF] |
||||
![]() |
H. Kataoka and S. Takada The role of thoracic ultrasonography for evaluation of patients with decompensated chronic heart failure J. Am. Coll. Cardiol., May 1, 2000; 35(6): 1638 - 1646. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Becker, B. Merkely, A. Bauer, L. Geller, L. Fazekas, K. D. Freigang, F. Voss, J. C. Senges, W. Kuebler, and W. Schoels Ventricular arrhythmias induced by endothelin-1 or by acute ischemia: a comparative analysis using three-dimensional mapping Cardiovasc Res, January 14, 2000; 45(2): 310 - 320. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.H. Davies and Y. Bashir Beta-blockers for heart failure-time to think the unthinkable? QJM, November 1, 1999; 92(11): 673 - 678. [Full Text] [PDF] |
||||
![]() |
O. Zolk, J. Quattek, G. Sitzler, T. Schrader, G. Nickenig, P. Schnabel, K. Shimada, M. Takahashi, and M. Bohm Expression of Endothelin-1, Endothelin-Converting Enzyme, and Endothelin Receptors in Chronic Heart Failure Circulation, April 27, 1999; 99(16): 2118 - 2123. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. J. Cowburn, J. G. F. Cleland, J. D. McArthur, M. R. MacLean, J. J. V. McMurray, H. J. Dargie, and J. J. Morton EndothelinB receptors are functionally important in mediating vasoconstriction in the systemic circulation in patients with left ventricular systolic dysfunction J. Am. Coll. Cardiol., March 15, 1999; 33(4): 932 - 938. [Abstract] [Full Text] [PDF] |
||||
![]() |
M Mundhenke, B Schwartzkopff, M Köstering, U Deska, R M Klein, and B E Strauer Endogenous plasma endothelin concentrations and coronary circulation in patients with mild dilated cardiomyopathy Heart, March 1, 1999; 81(3): 278 - 284. [Abstract] [Full Text] |
||||
![]() |
M. Hulsmann, B. Stanek, B. Frey, B. Sturm, D. Putz, T. Kos, R. Berger, W. Woloszczuk, G. Maurer, and R. Pacher Value of cardiopulmonary exercise testing and big endothelin plasma levels to predict short-term prognosis of patients with chronic heart failure J. Am. Coll. Cardiol., November 15, 1998; 32(6): 1695 - 1700. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Ferri, G. Properzi, G. Tomassoni, A. Santucci, G. Desideri, A. E. Giuliani, R. C. Starling, N. B. Ratliff, D. J. Cook, P. McCarthy, et al. Patterns of Myocardial Endothelin-1 Expression and Outcome After Cardiac Transplantation Circulation, April 16, 2002; 105(15): 1768 - 1771. [Abstract] [Full Text] [PDF] |
||||














